<DOC>
	<DOCNO>NCT02943577</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability rapastinel 450 milligram ( mg ) compare placebo adjunctive antidepressant therapy ( ADT ) patient major depressive disorder ( MDD ) partial response ADT .</brief_summary>
	<brief_title>A Study Rapastinel Adjunctive Therapy Major Depressive Disorder ( RAP-MD-03 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criteria MDD Current major depressive episode least 8 week exceed 18 month duration Visit 1 Have partial response ( &lt; 50 % improvement ) ongoing treatment protocolallowed antidepressant If female childbearing potential , negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test . DSM5based diagnosis disorder MDD primary focus treatment within 6 month Visit 1 Lifetime history meeting DSM5 criterion : 1 . Schizophrenia spectrum psychotic disorder 2 . Bipolar relate disorder 3 . Major neurocognitive disorder 4 . Neurodevelopmental disorder great mild severity severity impact participant 's ability consent , follow study direction , otherwise safely participate study 5 . Dissociative disorder 6 . Posttraumatic stress disorder 7 . MDD psychotic feature Significant suicide risk , judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>